MentionFox
Home › funding signals › Ritivel
Accelerator · announced

Ritivel (YC W26) — AI-native platform for Life-Sciences documentation

Ritivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies. Our AI agents draft CTDs, CSRs, INDs, and BLAs in minutes instead of weeks, helping drugs reach patients faster.

Ritivel is a Y Combinator company in the Winter 2026 batch. Its directory entry describes it as: AI-native platform for Life-Sciences Documentation. The founders listed are Pavan Kalyan (Founder/CEO), Nirmit Arora (Founder/CTO), Gunin Gupta (Founder/COO) (Y Combinator directory entry, January 14, 2026).

6 more companies from YC Winter 2026 ↓

Run the free check on Ritivel →

Sell to companies like Ritivel? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Ritivel

New accelerator entry · 2026-01-14 · the record

Winter 2026
batch
3
people
Early
stage
India
region
Open the record →

What the record says

BatchWinter 2026
Announced2026-01-14
StageEarly
StatusActive
Team size3
IndustryHealthcare
Sub-industryHealthcare -> Healthcare IT
SectorsGenerative AI, Compliance, Enterprise Software, Regtech, Biotechnology
RegionsIndia, South Asia
BasedBengaluru, KA, India
HiringNo
Sitehttps://www.ritivel.com
Previously known asRitivel, ritivel

Pitching, partnering or investing alongside them? See who really runs and owns Ritivel.

Free to see. No signup.

Keep reading

More on Ritivel and the records around it.

Also in YC Winter 2026

Same batch, Healthcare first.

What do you want to do with Ritivel?

Get the full cited report on Ritivel

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Ritivel: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

In their words

Ritivel is an AI-native workspace for regulatory and medical writing teams at life sciences companies. Our AI agents draft CTDs, CSRs, INDs, and BLAs in minutes instead of weeks, helping drugs reach patients faster. Every month a drug is delayed from reaching the market costs pharma companies ~$45M in lost revenue and more importantly, delays treatment for thousands of patients who need it. Yet regulatory teams are stuck in a painful, months-long process: synthesizing thousands of pages of clinical data, hunting through SharePoint folders for the right documents, chasing colleagues for missing inputs, and manually drafting submissions. Ritivel deploys AI agents that transform how regulatory teams work. Our agents generate comprehensive first drafts directly in Microsoft Word, following FDA formatting requirements and pulling from your existing clinical data and prior submissions. Every data point includes citations linked back to the original source, so reviewers can verify with one click. Connected to SharePoint and Veeva, our agents automatically source the right documents. Integrated with Outlook, they handle reminder emails and follow-ups automatically. We're engineers who previously built AI copilots at Microsoft Research. After 50+ conversations with pharma professionals, we discovered the critical bottleneck in regulatory submissions and built Ritivel to solve it.

Want the whole picture on Ritivel?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Ritivel: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Ritivel covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Ritivel: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.

Sourced from the company's Y Combinator directory entry.

RSS

Tools for this story

Each opens in a new tab, filled in for Ritivel. With no account yet, you sign up free and land on the result.

On these startup lists

Compliance and regtech startups Healthcare and health tech startups

Share this page

Is this your company?

Share the news. Sharing needs no account.

Ritivel: Accepted into Y Combinator Winter 2026
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/yc-ritivel
Last updated 2026-10-20
Primary record: Y Combinator directory entry
Ritivel (YC W26) — AI-native platform for Life-Sciences documentation. MentionFox, 2026-10-20. https://mentionfox.com/funding/yc-ritivel